Exchange: NASDAQ·Updated 01:12 PM EDT
News
all
press releases
AI, Biotech and Billion-Dollar Deals Ignite Market Momentum as Breakout Companies Make Big Moves
A fresh round of corporate announcements is highlighting several of Wall Street's strongest investment themes. $JUNS, $KBLB, $KIDZ, $HIHO, $VIVK, $UTZ
24-7 Market News
More News
Jupiter Neurosciences Lands Potential $100 Million Psychedelic Drug Deal as PharmAla Licenses ALA-002
Momentum continues to build across the emerging psychedelic medicine sector as PharmAla Biotech (OTCQB:MDXXF) announced a definitive licensing agreement granting Jupiter Neurosciences (NASDAQ:JUNS) exclusive rights to develop, manufacture, and commercialize ALA-002 in the United States. The agreement, valued at up to approximately US$100 million in potential consideration, reflects the growing interest in next-generation neuropsychiatric therapies and strategic partnerships designed to advance promising clinical assets while managing development risk.
24-7 Market News
Micro-Cap Biotech Stocks Surge After Breakthrough Psychedelics Licensing Announcement
The psychedelics market continues to expand rapidly as researchers gain a deeper understanding of its potential therapeutic benefits. Today, a leader in the sector announced a partnership with another micro-cap biotech company to further advance its development efforts in the space. Investors responded positively to the news, sending shares of both companies sharply higher following the announcement.PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) announced that it has signed a term sheet with Jupiter Neurosciences, Inc. (NASDAQ: JUNS) to grant the company exclusive perpetual U.S. ...
AllPennyStocks.com
Micro-Cap Biotech Stocks Surge After Breakthrough Psychedelics Licensing Announcement
The psychedelics market continues to expand rapidly as researchers gain a deeper understanding of its potential therapeutic benefits. Today, a leader in the sector announced a partnership with another micro-cap biotech company to further advance its development efforts in the space. Investors responded positively to the news, sending shares of both companies sharply higher following the announcement.PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) announced that it has signed a term sheet with Jupiter Neurosciences, Inc. (NASDAQ: JUNS) to grant the company exclusive perpetual U.S. ...
AllPennyStocks.com
Jupiter Stock Soars After $100 Million ALA-002 Licensing Deal
Jupiter Neurosciences shares are rising Wednesday after it announced the acquisition of US licensing rights to ALA-002 from Pharmala Biotech.read more...
Benzinga
JUNS Stock Sees Best Single-Day Gains In Almost A Year On $100M MDMA Drug Licensing Deal  – Retail Expects Shares To Hit $1
Jupiter Neurosciences signed a term sheet to acquire exclusive U.S. licensing rights to an MDMA-based drug candidate developed by PharmAla Biotech.
Stocktwits
Jupiter Neurosciences Investor News: Rosen Law Firm Encourages Jupiter Neurosciences, Inc. Investors to Inquire About Securities Class Action Investigation JUNS
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Jupiter Neurosciences, Inc. (NASDAQ: JUNS) resulting...
Business Wire
Rosen Law Firm Encourages Jupiter Neurosciences, Inc. Investors to Inquire About Securities Class Action Investigation JUNS
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Jupiter Neurosciences, Inc. (NASDAQ: JUNS) resulting...
Business Wire

Advertisement|Remove ads.